Loading…
Loading…
CMXC (Cell MedX Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
VANCOUVER, BC / ACCESSWIRE / November 4, 2024 / StimCell Energetics Inc. (formerly "Cell MedX Corp.") (OTC PINK:CMXC) ("StimCell", or the "Company") a biotech company targeting cellular energy to promote anti-aging, longevity and general wellness, is pleased to announce a series of significant corporate changes designed to redefine the Company's strategic vision. StimCell Energetics Inc. Effective immediately, the Company has completed a corporate name change from "Cell MedX Corp." to "StimCell Energetics Inc." and completed a reverse split of its common stock on a 1 new share for 15 old shares basis (the "Reverse Split").
Vancouver, British Columbia--(Newsfile Corp. - March 19, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces that it has closed a non-brokered private placement offering (the "Offering") by issuing 2,500,000 units (each a "Unit") at US$0.03 per Unit for total gross proceeds of US$75,000. Each Unit sold under the Offering consists of one share in the common stock of the Company and one share purchase warrant (the "Warrant") expiring on March 12, 2026.
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces the resignation of Brad Hargreaves from the Board of Directors of the Company. The resignation of Mr.
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, is pleased to announce the appointment by the board of directors of Dr. George Adams as Chairman of the Board. Dr. Adams has served on the board of directors of the Company since March 23, 2018 and was most recently CEO of Ventripoint Diagnostics, a medical devices company involved in the development of heart diagnostic devices for patients with heart disease.
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that Mr. Dwayne Yaretz has resigned as Chief Executive Officer of the Company and Mr.
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2023) - Cell MedX Corp. ("Cell MedX" or the "Company") (OTC Pink: CMXC) announces that on November 22, 2023, the British Columbia Securities Commission (the "BCSC") issued an order revoking the Cease Trade Order previously issued by the Commission on October 11, 2022 (the "CTO"). The CTO was previously issued by the BCSC for Cell MedX failing to file audited financial statements and related management's discussion and analysis and an annual information form within the required time.
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has appointed Mr. Dwayne Yaretz, Mr.